Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer

Clinical Cancer Research

Volumn 12, Issue 7 I, 2006, Pages 2216-2223

  Popadiuk, Cathy M ^a   Xiong, Jieying ^a   Wells, Malcolm G ^a   Andrews, Phillip G ^a   Dankwa, Kweku ^a   Hirasawa, Kensuke ^a   Lake, Blue B ^a   Kao, Kenneth R ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; PROTEIN PYGOPUS 2; UNCLASSIFIED DRUG; WNT PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL COUNT; CLEAR CELL CARCINOMA; COLONY FORMATION; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; NORTHERN BLOTTING; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; T LYMPHOCYTE; TISSUE CULTURE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NEOPLASMS, EXPERIMENTAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OVARIAN NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33646258514     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2433     Document Type: Article

References (38)

1. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-50.
2. Pinto D, Clevers H. Wnt, stem cells and cancer in the intestine. Biol Cell 2005;97:185-96.
3. Bienz M. β-Catenin: a pivot between cell adhesion and Wnt signalling. Curr Biol 2005;15:R64-7.
4. Belenkaya TY, Han C, Standley HJ, et al. Pygopus encodes a nuclear protein essential for wingless/Wnt signaling. Development 2002;129:4089-101.
5. Kramps T, Peter O, Brunner E, et al. Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear β-catenin-TCF complex. Cell 2002;109:47-60.
6. Parker DS, Jemison J, Cadigan KM. Pygopus, a nuclear PHD-finger protein required for Wingless signaling in Drosophila. Development 2002;129:2565-76.
7. Thompson B, Townsley F, Rosin-Arbesfeld R, et al. A new nuclear component of the Wnt signalling pathway. Nat Cell Biol 2002;4:367-73.
8. Townsley FM, Cliffe A, Bienz M. Pygopus and Legless target Armadillo/β-catenin to the nucleus to enable its transcriptional co-activator function. Nat Cell Biol 2004;6:626-33.
9. Hoffmans R, Basler K. Identification and in vivo role of the Armadillo-Legless interaction. Development 2004;131:4393-400.
10. Hoffmans R, Stadeli R, Basler K. Pygopus and legless provide essential transcriptional coactivator functions to armadillo/β-catenin. Curr Biol 2005;15:1207-11.
11. Townsley FM, Thompson B, Bienz M. Pygopus residues required for its binding to legless are critical for transcription and development. J Biol Chem 2004;279:5177-83.
12. Verma UN, Surabhi RM, Schmaltieg A, et al. Small interfering RNAs directed against β-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003;9:1291-300.
13. Li Y, Welm B, Podsypanina K, et al. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci U S A 2003;100:15853-8.
14. Kildal W, Risberg B, Abeler VM, et al. β-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients. Eur J Cancer 2005;41:1127-34.
15. Palacios J, Gamallo C. Mutations in the β-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 1998;58:1344-7.
16. Wu R, Zhai Y, Fearon ER, et al. Diverse mechanisms of β-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 2001;61:8247-55.
17. Zhai Y, Wu R, Schwartz DR, et al. Role of β-catenin/ T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas. Am J Pathol 2002;160:1229-38.
18. Auersperg N, Siemens CH, Myrdal SE. Human ovarian surface epithelium in primary culture. In Vitro 1984;20:743-55.
19. Lake BB, Kao KR. Pygopus is required for embryonic brain patterning in Xenopus. Dev Biol 2003;261:132-48.
20. Ju ST, Panka DJ, Cui H, et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995;373:444-8.
21. Reynolds JN, Prasad A, Gillespie LL, et al. Developmental expression of functional GABAA receptors containing the γ2 subunit in neurons derived from embryonal carcinoma (P19) cells. Mol Brain Res 1996;35:11-8.
22. Rorke S, Murphy, S, Khalifa, M, et al. Prognostic significance of BAG-1 expression in nonsmall cell lung cancer. lnt J Cancer 2001;95:317-22.
23. Elkas JC, Baldwin RL, Pegram M, et al. A human ovarian carcinoma murine xenograft model useful for preclinical trials. Gynecol Oncol 2002;87:200-6.
24. Lee CM, Shvartsman H, Deavers MT, et al. β-catenin nuclear localization is associated with grade in ovarian serous carcinoma. Gynecol Oncol 2003;88:363-8.
25. Bell DA Origins and molecular pathology of ovarian cancer. Mod Pathol 2005;18 Suppl 2:S19-32.
26. Seidman JD, Kurman RJ. Pathology of ovarian carcinoma. Hematol Oncol Clin North Am 2003;17:909-25, vii.
27. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, et al. Loss of β-catenin is associated with poor survival in ovarian carcinomas. Int J Gynecol Pathol 2004;23:337-46.
28. Faleiro-Rodrigues C, Macedo-Pinto IM, Maia SS, et al. Biological relevance of E-cadherin-catenin complex proteins in primary epithelial ovarian tumors. Gynecol Obstet Invest 2005;60:75-83.
29. Bienz M. The subcellular destinations of APC proteins. Nat Rev Mol Cell Biol 2002;3:328-38.
30. Ciani L, Krylova O, Smalley MJ, et al. A divergent canonical WNT-signaling pathway regulates microtubule dynamics: dishevelled signals locally to stabilize microtubules. J Cell Biol 2004;164:243-53.
31. See HT, Kavanagh JJ, Hu W, Bast RC. Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int J Gynecol Cancer 2003;13:701-34.
32. Gleave ME, Monia BP. Antisense therapy for cancer. Nat Rev Cancer 2005;5:468-79.
33. Skilling JS, Squatrito RC, Connor JP, et al. p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines. Gynecol Oncol 1996;60:72-80.
34. Ma X, Wang S, Zhou J, et al. Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides. Oncol Rep 2005;14:275-9.
35. Mullen P, McPhillips F, MacLeod K, et al. Antisense oligonucleotide targeting of Raf-1: importance of raf-1 mRNA expression levels and raf-1-dependent signaling in determining growth response in ovarian cancer. Clin Cancer Res 2004;10:2100-8.
36. Li J, Sasaki H, Sheng YL, et al. Apoptosis and chemoresistance in human ovarian cancer: is Xiap a determinant? Biol Signals Recept 2000;9:122-30.
37. Yuan B, Mi R. [Antisense oligodeoxynucleotides of human telomerse catalytic sub-unit inhibits telomerase activity and proliferation in SKOV3 and COC1]. Zhonghua Fu Chan Ke Za Zhi 2002;37:198-201.
38. Kushner DM, Paranjape JM, Bandyopadhyay B, et al. 2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells. Gynecol Oncol 2000;76:183-92.